Acadia Pharmaceuticals Inc.

Allergan, Inc.

Sinntaxis Ab

Ge Healthcare Limited

Roger Olsson

Magnus Gustafsson

Birgitte Winther Lund

Beat Theodor Weber

Marlon Carlos

Fredrik Ek

Mikael Hillgren

Ethan S Burstein

Sagun Tandel

Matthew J Fleming

Jörgen Ohlsson

Lene Hyldtoft

Andreas Philipp Boudier

Karl Erik Jansson

Larisa Yudina Wahlström

Björn Gustav Borgström

Niklas Patrik Sköld

Henrik Von Wachenfeldt

Fabrice Piu

Nathalie Schlienger

Mikkel Boas Thygesen

Jan Pawlas

Fabrizio Badalassi

Jorgen Eskildsen

Edward Robins

Alex Gibson

Rasmus Lewinsky

Vladimir Sherbukhin

Alma Fejzic

Tadeusz Wieloch

Magnus Gustav Wilhelm Bergner

Birgitte Lund

Carin Sjölund

James Nairne

Kerstin Beirup

Anne Eeg Knapp

Karsten Ruscher

Brigitte Winther Lund

Carin SJÖLUND

Ethan Burstein

Joel Castillo

Veronique Morisson Iveson

The present disclosure relates to compounds according to Formula (I), useful for treating diseases.

Compounds, salts thereof and methods for treatment of diseases

Disclosed herein are methods for obtaining N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N-(4-(2-methylpropyloxy)phenylmethyl) carbamide (pimavanserin) comprising the step of contacting an intermediate according to Formula (A) or a salt thereof, with an intermediate Formula B, or a salt thereof, to produce pimavanserin or a salt thereof wherein Y is &#x2014;ORor &#x2014;NRR; Ris hydrogen or substituted or unsubstituted heteroalicyclyl, Ris substituted or unsubstituted aralkyl; X is &#x2014;ORor &#x2014;NRR; (wherein Ris hydrogen or substituted or unsubstituted Calkyl and one of Rand Ris hydrogen and the other is hydrogen or N-methylpiperidin-4-yl); and Ris &#x2014;OCHCH(CH)or F; Also disclosed herein is the tartrate salt of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide and methods for obtaining the salt.

Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c

The present disclosure relates to compounds according to Formulae (I), (II) and (VIII), useful for treating diseases.

The present disclosure relates to the use of negative allosteric modulators (NAMs) of the metabotropic glutamate receptor 5 (mGluR5) in the treatment of a mature brain damage, such as damage after stroke.

Negative allosteric modulators of MGLUR5 for use in the treatment of mature brain damages

Disclosed herein are methods for obtaining N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (pimavanserin) comprising the step of contacting an intermediate according to Formula (A) or a salt thereof, with an intermediate Formula B, or a salt thereof, to produce pimavanserin or a salt thereof wherein Y is &#x2014;ORor &#x2014;NRR; Ris hydrogen or substituted or unsubstituted heteroalicyclyl, Ris substituted or unsubstituted aralkyl; X is &#x2014;ORor &#x2014;NRR; (wherein Ris hydrogen or substituted or unsubstituted Calkyl and one of Rand Ris hydrogen and the other is hydrogen or N-methylpiperidin-4-yl); and Ris &#x2014;OCHCH(CH)or F; Also disclosed herein is the tartrate salt of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N&#x2032;-(4-(2-methylpropyloxy)phenylmethyl) carbamide and methods for obtaining the salt. 

Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form

Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form C

Compounds of formula (I) and methods are provided for the treatment of disease or conditions in which modification of cholinergic, especially muscarinic receptor activity, has a beneficial effect. 

Muscarinic agonists

Disclosed herein are novel di-aromatic compounds of the general formula (I). Also pharmaceutical compositions comprising the novel compounds and the use of the novel compounds in treatment and prevention of diseases and disorders related to estrogen receptors are disclosed. Furthermore, methods for treating and preventing diseases and disorders related to estrogen receptors by administration of the novel compounds are disclosed. 

Diphenyl substituted cyclohexane derivatives, useful as modulators of the estrogen receptors beta

Disclosed herein are methods of treatment and prevention of diseases and disorders related to estrogen receptors comprising administering novel di-aromatic compounds to patients in need thereof.

Compounds with activity at estrogen receptors

Disclosed herein are compounds of Formula I as disclosed herein, methods of modulating the activity of an estrogen receptor and methods of treating a disorder associated with estrogen receptors.

Disclosed herein are novel di-aromatic compounds and methods for using various di-aromatic compounds for treatment and prevention of diseases and disorders related to estrogen receptors.

Disclosed herein are analogs of clozapine and pharmaceutically acceptable salts, esters, amides, or prodrugs thereof, methods of synthesizing the analogs; and methods of using the analogs for treating neuropsychiatric disorders. In some embodiments, the analogs are amino substituted diaryl[a,d]cycloheptenes.

[object Object]

Growing community of inventors

Bunkeflostrand, Sweden

Roger Olsson